Abstract: The invention concerns the use of recombinant nucleotides sequences containing cDNA coding for a preduodenal lipase, or any sequence derived from this cDNA, for transforming plant cells in order to obtain recombinant preduodenal lipase or polypeptide derivatives. The invention also concerns the use of genetically modified plants or parts thereof, or extracts of these plants or the use of recombinant preduodenal lipase or résultant polypeptide derivatives in the field of foodstuffs, or for producing medicaments, or in industry.

Abstract: Diazepinoindoles of formula (I), ##STR1## wherein A is mono- to trisubstituted aryl or heteroaryl, and B is an --OR.sub.1 or --NR.sub.2 R.sub.3 group where R.sub.1, R.sub.2 and R.sub.3 are particularly hydrogen, and racemic forms, enantiomers and pharmaceutically acceptable salts thereof, as phosphodiesterase IV inhibitors, are disclosed.

Abstract: The invention relates to diazepinoindoles of formula: ##STR1## in which R is hydrogen, lower alkyl or lower alkoxy; A is aryl or nitrogen-containing heteroaryl, each of which is optionally substituted by from one to three groups of halogen, lower alkyl, haloalkyl, lower alkoxy and acetamido, or their racemic forms, isomers or pharmaceutically acceptable salts, wherein for the racemic forms of the (S) configuration, A is not phenyl, haloalkyl, or 2-indolyl when R is hydrogen, and for the racemic forms of the (R) configuration, A is not 2-indolyl when R is hydrogen. Also, the invention relates to a method for inhibiting cyclic nucleotide phosphodiesterase activity by administering these compounds to a subject in an amount which is therapeutically effective to inhibit cyclic nucleotide phosphodiesterase activity.

Abstract: New 2-(arylalkenyl)azacycloalkane derivatives which are ligands for sigma receptors, of the formula (I) ##STR1## in which: Ar is aryl or heteroaryl, optionally mono- to trisubstituted,m has the value 1 or 2,n has the value 1 to 3,R is phenyl, or cycloalkyl containing 3 to 7 carbon atoms,their isomers and their addition salts. Medicinal drugs which are antipsychotic agents and are useful in gastroenterology.

Abstract: The present invention relates to dog gastric lipase as obtained by genetic engineering as well as to the nucleotide sequence encoding this recombinant DGL. It also relates to the use of this recombinant DGL for the production of pharmaceutical compositions intended especially for the treatment of pathologies linked to the insufficiency, or even the absence, of secretion of lipases in the body of an individual.

Abstract: Allylaminoesters of the formula (I): ##STR1## in which: R.sub.1 is H or low-molecular-weight alkyl,R.sub.2 is low-molecular-weight alkyl, cycloalkyl, or low-molecular-weight phenylcycloalkyl, pyridyl or phenyl, low-molecular-weight phenylalkyl, low-molecular-weight diphenylalkyl, low-molecular-weight phenylalkenyl, in which the phenyl cycle may be mono-, di- or trisubstituted by chlorine atoms, low-molecular-weight alkyl radicals, low-molecular-weight alkoxy, or trifluoromethyl, acetamide or acetyloxy radicals, their racemic forms, their (S) enantiomers and their addition salts. Also, antiallergic drugs containing the same.

Abstract: Process for the treatment of painful syndromes, especially local and/or visceral, consisting in the parenteral or topical administration of a therapeutically effective quantity of the (-) tartrate of (+)-(R)-1-[(3,4,5-trimethoxy)benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-prop ylamine.

Abstract: Enantiomers of (S) configuration of formula (I) ##STR1## in which R is H or methyl, with antiallergic and in particular antihistaminic activity, useful as medicinal products.

Abstract: New cycloalkylalkylamines which are sigma-receptor ligands of formule (I) ##STR1## in which: R.sub.1 is H or lower alkyl; X and Y are H, OH, lower alkyl, lower alkoxy, halogen or nitrile; V.sub.1 and V.sub.2 together form a double bond attached to an oxygen atom or to a hydroxyimino radical, or are linked as an ethylenedioxy chain; A represents a valency bond, an oxygen atom, a methylene or an ethylene group; m is equal to 0, 1 or 2; n has the value of an integer from 1 to 5. Psychotropic drug which is also useful in gastroenterology.

Abstract: Method of resolution of chiral hydantoins of the general formula I ##STR1## in which: R.sub.1 designates a lower alkyl radical comprising 1 to 5 carbon atoms in linear or branched chain,R.sub.2 designates a phenyl radical, possibly mono-, di-, or tri-substituted by lower alkyl or alkoxy radicals or halogen atoms, whether identical of different, or a heteroaryl radical containing a ring of 5 to 7 members in which the sole hetero atom is nitrogen, oxygen or sulfur, or else an aralkyl radical the alkyl part of which comprises one or two carbon atoms and the aryl ring is a phenyl group possibly mono-, di- or tri-substituted by radicals which are lower alkyl or alkoxy radicals or halogen atoms, whether identical or different. The hydantoin (I) to be resolved is dissolved in an alcohol or an alkaline solution, and an enantiomer of .alpha.

Abstract: (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylam ine of formula ##STR1## is a medicament of use in gastroenterology.

Abstract: (+)-1-[(3,4,5-trimethoxy)-benzyloxymethyl]-1-phenyl-N,N-dimethyl-n-propylam ine of formula ##STR1## is a medicament of use in gastroenterology.

Abstract: The present invention relates to propanamines of general formula (I) ##STR1## in which: R1 is a phenyl radical optionally mono-, di- or trisubstituted in an identical or different manner with halogen atoms, or lower alkyl, lower haloalkyl or lower alkoxy radicals;R2 is a lower alkyl radical,R3 and R4 are a hydrogen atom or a lower alkyl, lower alkenyl or lower cycloalkyalkyl radical,R5 is a 5-to 7-membered cycloalkyl radical or a phenyl radical, andW represents a heterocycle .dbd.C[Q--(CH.sub.2).sub.n --Q] in which Q is an oxygen or sulfur atom and n is 2 or 3,and their acid addition salts with pharmaceutically acceptable acids. The invention also relates to antidiarrheal pharmaceutical compositions comprising the claimed propanamines.

Abstract: A compound which is a propanamine of general formula (I) ##STR1## in which: R1 is a phenyl radical optionally mono-, di- or trisubstituted,or is a 5- or 6-membered monocyclic heteroaryl radical in which the single heteroatom is nitrogen, oxygen or sulfur,R2 is a lower alkyl radical,R3 and R4 are a hydrogen atom or a lower alkyl, lower alkenyl or lower cycloalkylalkyl radical,or, together with the nitrogen atom to which they are attached, form a saturated 5- to 6-membered heterocycle comprising only one heteroatom,R5 is a 5- to 7-membered cycloalkyl radical, a phenyl radical or a 5- or 6-membered monocyclic heteroaryl radical,and W representsa group .dbd.CH--QH,or a heterocycle .dbd.C[Q--(CH2)n--Q],or a group .dbd.C.dbd.Q, in which groupsQ is an oxygen or sulfur atom,n has the value 2 or 3,W being .dbd.C.dbd.Q only when R3 and R4 are not both hydrogen, and their additions salts with pharmaceutically acceptable acids.

Abstract: N-Cycloalkylalkylamines of formula I: ##STR1## in which: R1 is phenyl which is optionally mono-, di- or trisubstituted by halogens or lower alkyl, haloalkyl or lower alkoxy radicals, or is an aromatic heterocyclic radical having 5 to 7 chain members, in which the hetero atom is nitrogen, oxygen or sulphur,R2 is lower alkyl,R3 is hydrogen or lower alkyl,m has the value of 1 or 2,R4 is cycloalkyl --CH(CH2)n, in which a carbon atom may carry a radical Rx, which is lower alkyl or phenyl; and in which n has the values from 2 to 5,R5 is phenyl, which can be mono-, di- or trisubstituted by halogens or by lower alkoxy radicals, andQ represents an ethylene-1,2-diyl group --CH.dbd.

Abstract: Benzodiazepines of formula ##STR1## in which R.sup.9 is hydrogen or chlorine, R10 is phenyl, possibly substituted, R11 is hydrogen, R12 is oxygen or sulphur, R13 is an NH group, Ar is aromatic or heteroaromatic comprising one or more rings and in which, in particular, A is an ethylene or trimethylene bridge; e is 1 or 2; which are gastrin antagonists and/or central antagonists of cholecystokinin.

Abstract: Process for the preparation of a gastric lipase. The stomachs of rabbits or horses undergo extraction by an acid aqueous medium, the lipase extract is salted out by the addition of hydrosoluble salts then, by filtration on a molecular sieve, followed by separation using ion exchange chromatography, an elution fraction containing the lipase is collected.Medicament for fighting against malabsorptions of fatty substances.

Abstract: 3,20-dione-11.beta.-hydroxypregn-4-ene-21-thioacetate-17-butyrate and 3,20-dione-11.beta.-hydroxypregn-4-ene-21-thiopropionate-17-butyrate, are anti-inflamatory agents.

Abstract: Substituted ethylamines of the formula ##STR1## wherein R.sub.1 is phenyl optionally mono-, di- or trisubstituted by halogen, lower alkyl, lower haloalkyl or lower alkoxy, or is an aromatic heterocycle having 5 to 7 chains wherein the heteroatom is nitrogen, oxygen or sulfur,R.sub.2 is lower alkyl,R.sub.3 and R.sub.4, each independently, represent hydrogen, lower alkyl or lower alkenyl,R.sub.5 is phenyl optionally mono-, di- or trisubstituted by halogen or lower alkoxy or is an aromatic heterocycle having 5 to 7 chains wherein the heteroatom is nitrogen, oxygen or sulfur andQ represents a --CH.dbd.CH-- ethylene group or a 1,2-diyl ##STR2## propane group, their acid addition salts and their optically active forms. These substituted ethylamines have psycotropic properties and are useful as medicines.

Abstract: Aminoalcohols of formula: ##STR1## in which R.sub.1 is alkyl, R.sub.2 H or alkyl, R.sub.3 in particularly H, alkyl, phenylakyl, alkanoyl, phenylalkanoyl, in which N, R.sub.2 and R.sub.3 together form a heterocycle saturated with 5 to 7 chain links.Analgesic medicaments.